[Serum determination of CA 19-9 in patients with digestive cancers and its diagnostic evaluation].
The precision of CA 19-9 RIA kit was evaluated by recovery, reproducibility and dilution test with very satisfactory results. The CA 19-9 value in sera from 52 healthy individuals and from 224 patients with gastric intestinal cancer and other benign disease, showed an increased positive rate in several cases of gastric intestinal cancer. For example, the positive rate in pancreatic cancer, bile duct cancer, colo-rectal cancer, gastric cancer, esophagus cancer, primary biliary cirrhosis diabetes mellitus, liver cirrhosis and chronic hepatitis was 60%, 75%, 55.6%, 45.6%, 20%, 28.6%, 22.7%, 13.7% and 1.7% respectively. By contrast, values from patients with acute hepatitis, fulminant hepatitis, fatty liver, gastric duodenal ulcer, pancreatitis, and primary liver cancer were within the normal range. In this study, CA 19-9 RIA were found to be significant as an adjunct in the management of patients with gastrointestinal cancer, especially pancreatic cancer, and bile duct cancer.
D000951:Antigens, Neoplasm / Q000097:blood*; D015295:Antigens, Tumor-Associated, Carbohydrate; D001650:Bile Duct Neoplasms / Q000097:blood; D003110:Colonic Neoplasms / Q000097:blood; D005069:Evaluation Studies as Topic; D005770:Gastrointestinal Neoplasms / Q000097:blood / Q000175:diagnosis*; D006801:Humans; D008107:Liver Diseases / Q000097:blood; D010190:Pancreatic Neoplasms / Q000097:blood; D011933:Reagent Kits, Diagnostic / Q000592:standards*; D012004:Rectal Neoplasms / Q000097:blood; D013274:Stomach Neoplasms / Q000097:blood
D000951:Antigens, Neoplasm; D015295:Antigens, Tumor-Associated, Carbohydrate; D011933:Reagent Kits, Diagnostic